SEC Form 424B5 filed by NeOnc Technologies Holdings Inc.
$NTHI
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
EFFECT - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
424B5 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
CALABASAS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has achieved a key milestone toward closing its previously announced strategic transaction with Quazar Investment: formal approval from NeOnc's Board of Directors. On June 30, 2025, NeOnc's Board unanimously approved the company's participation in the contemplated $50 million equity investment and MENA region expansion under a non-binding term sheet with Quazar. This Board approval marks the first of five required milestones in the transaction c
CALABASSAS, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, has joined the Russell Microcap® Index following the conclusion of the 2025 Russell indexes annual reconstitution. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks ranking them by total market capitalization. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes pr
CALABASAS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has signed a non-binding term sheet with Quazar Investment to form a new UAE-based investment and clinical platform focused on the Middle East and North Africa (MENA) region. The non-binding term sheet outlines the formation of NuroMENA Holdings Ltd, a wholly owned holding company of NeOnc, which will oversee the incorporation of NuroCure, an Abu Dhabi onshore operating subsidiary. NuroCure will be responsible for initiating and managing clinical tria
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
3 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4/A - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule Appointment bolsters FDA approval path while company explores AI and quantum computing to enhance drug delivery platform CALABASAS, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced the appointment of Josh Neman, PhD as its new Chief Clinical Officer (CCO). Dr. Neman brings with him a distinguished career at the intersection of cancer neuroscience, translational